[ad_1]
Russia announced today that its Sputnik V vaccine against COVID-19, which is being developed by the Gamaleya National Center for Epidemiology and Microbiology in Moscow, is 95% effective.
The results are only preliminary, but they are quite interesting.
Anyone who has followed the news about vaccines, more specifically about their effectiveness, easily perceives that the results are encouraging.
The North American Pfizer and the German BioNTech were the first to announce it. Pfizer initially revealed that their vaccine was 90% effective and recently updated the data to 95% (after more results). The Modern Pharmaceuticals report revealed that its vaccine is "almost 95% effective." The Oxford vaccine is 90% effective with dosing ...
Sputnik V vaccine guarantees 95% effectiveness
The Research Center reported that the results were obtained from volunteers, 42 days after the injection of the first dose. The result obtained is the same as that of the vaccine from the North American pharmaceutical company Pfizer. Remember that in a first advertisement the percentage of effectiveness was 92%. Russia's vaccine is based on freeze-drying technology, which will significantly facilitate its transportation to international markets, including hard-to-reach regions and others with a tropical climate.
The price, which will be less than 10 dollars a dose (about eight euros), is twice that of the vaccines that use mRMA, that is, the North American Moderna and Pfizer.
Currently, about 40 thousand volunteers participate in phase three, more than half received the first dose and the rest the first and second. The first batch of Sputnik V for the foreign market will reach customers in January 2021 based on agreements already signed with foreign partners.
Russia was the first country to register a COVID-19 vaccine for public use in August.
Read also ...
[ad_2]
